tbuckley/cabot-search huggingface dataset:
Carcinogenicity of Chlorinated Methane and Ethane Compounds Administered in Drinking Water to Mice
Authors: James E. Klaunig, Randall J. Ruch, Michael A. Pereira
Journal: Environmental Health Perspectives (1986)

The chlorinated hydrocarbons chloroform (CHCl3), 1,1-dichlorethane (1,1-DCE) and 1,2-dichloroethane (1,2-DCE) have been detected in finished drinking water. When administered to B6C3F1 mice by gavage in corn oil, these compounds have been shown to induce hepatic tumors. The present study examines the effect on liver tumor incidence of continuous treatment of CHCl3 (600 mg/L and 1800 mg/L), 1,1-DCE (835 mg/L and 2500 mg/L), and 1,2-DCE (835 mg/L and 2500 mg/L) administered in drinking water to male B6C3F1 mice using a two-stage (initiation/promotion) treatment protocol. Seventy 4-week-old male B6C3F1 mice constituted each treatment group. Of these mice, 35 were initiated by treatment with diethylnitrosamine (DENA) (10 mg/L) in the drinking water for 4 weeks. The remaining 35 received deionized drinking water. Each group was subsequently treated with one of two concentrations of CHCl3, 1,1-DCE, or 1,2-DCE in drinking water for 52 weeks. An additional group received phenobarbital (PB) (500 mg/L) and served as the positive control for liver tumor promotion. Mice were sampled after 24 weeks (10 mice) and 52 weeks (25 mice). At sampling, liver and lung tumors were detected. None of the compounds increased the number or incidence of lung or liver tumors by themselves. PB promoted liver tumor formation (but not lung tumors) in the DENA-initiated mice. 1,1-DCE and 1,2-DCE did not affect the incidence or number of liver or lung tumors in the DENA-initiated animals. CHCl3, however, inhibited liver and lung tumorigenesis in the DENA-initiated mice.
Late-Breaking Clinical Trial Abstracts
Authors: Bryan Williams, Olivier Bertrand, John Alexander
Journal: Circulation (2005)

Brachial blood pressure (BP) measurements are used to monitor the efficacy of BP lowering drugs.Different BP lowering drugs could have differing effects on central aortic pressures and thus cardiovascular outcome, despite similar effects on brachial BP.The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) examined the impact of two blood pressure lowering regimens; conventional therapy (atenololϮthiazide), versus contemporary therapy (amlodipineϮperindopril) in 19,257 patients with hypertension.The CAFE ´study, a sub-study of ASCOT, provides the first analysis of the impact of two different BP lowering regimens on derived central aortic pressures and hemodynamics.Hypothesis: i) different BP-lowering regimens will produce different effects on central aortic pressures/hemodynamics despite similar brachial blood pressures, and ii) this would contribute to different clinical outcomes in ASCOT.Design/Methods: The CAFE study recruited 2,199 patients in 5 ASCOT study centres.CAFE baseline demographics were representative of the ASCOT population.Radial artery applanation tonometry and pulse wave analysis (SphygmoCor © ) was used to derive central aortic pressures and hemodynamic indices.Over 17,000 central hemodynamic measurements were recorded on repeated visits, for up to 5 years.Results: Brachial BP differed little between treatment groups (-0.7/1.6mmHg, in favour of amlodipine).However, there were substantial reductions in trial-averaged values for central aortic pressures and hemodynamic indices in favour of the amlodipine regimen; central aortic systolic BP (-4.3mmHgϮ 0.5,Ͻ0.0001),central aortic pulse pressure (-3.0mmHgϮ 0.5, Ͻ0.0001) and augmentation index:(-5.8%Ϯ 0.4, Ͻ0.0001).In ASCOT, amlodipine-based treatment was associated with significant reductions in major cardiovascular and renal outcomes and death.In the CAFE cohort within ASCOT, central pulse pressure was a significant determinant of total cardiovascular and renal events/procedures, using a Cox proportional hazards model (unadjusted:pϽ0.0001,adjusted for baseline variables: pϽ0.05).Conclusion: The CAFE study demonstrates for the first time in a large clinical outcomes trial, that BP lowering drugs have profoundly different effects on central aortic pressures and hemodynamics, despite a similar impact on brachial blood pressure.Brachial BP is therefore, an imperfect surrogate for the effects of BP lowering drugs on central aortic pressures.Moreover, central pulse pressure appears to be an important determinant of clinical outcomes.These findings: i) provide a novel mechanism to explain the different clinical outcomes between the two BP-treatment arms in ASCOT and potentially other BP-lowering treatment trials, and ii) may have significant implications for treatment guidelines.
Baseline Data Incorrect
Journal: JAMA (2016)

Karen Bearss, PhD; Cynthia Johnson, PhD; Tristram Smith, PhD; Luc Lecavalier, PhD; Naomi Swiezy, PhD; Michael Aman, PhD; David B. McAdam, PhD; Eric Butter, PhD; Charmaine Stillitano, MSW; Noha Minshawi, PhD; Denis G. Sukhodolsky, PhD; Daniel W. Mruzek, PhD; Kylan Turner, PhD; Tiffany Neal, PhD; Victoria Hallett, PhD; James A. Mulick, PhD; Bryson Green, MS; Benjamin Handen, PhD; Yanhong Deng, MPH; James Dziura, PhD; Lawrence Scahill, MSN, PhD
An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide
Authors: R. K. Fuller
Journal: JAMA (1977)

Previous studies demonstrated the effectiveness of diuretics in mobilizing fluid, but frequent complications occur with their use in treating ascites. To develop an effective but safe regimen for treatment of cirrhotic ascites, a two-part crossover study was done. Subjects with life-threatening complications of cirrhosis were excluded. In part one it was demonstrated that a sixday diuretic regimen with dietary sodium restriction of 10 mEq/day is safe and more effective than sodium restriction alone. In part two the duration of diuretic therapy was safely extended from six to nine days with mobilization of significantly more fluid. Careful selection of subjects, use of diuretics in modest dosages for brief periods of time, and daily monitoring of subjects were important for the success of this study. (<i>JAMA</i>237:972-975, 1977)
NIMG-30. PREOPERATIVE PREDICTORS OF MALIGNANCY IN NON-ENHANCING GLIOMA IN THE ERA OF MOLECULAR CLASSIFICATION
Authors: Philip Dao Trong, Jessica Jesser, Andreas von Deimling, Samuel Kilian, Christel Herold-Mende, Andreas Unterberg, Christine Jungk
Journal: Neuro-Oncology (2018)

able challenge.Radiologic changes following CAR T-cell therapy may include inflammation, which may be misinterpreted as disease progression, resulting in premature termination of the treatment.The iRANO criteria provides a 'limbo window' of up to six months from the start of immunotherapy during which radiologic worsening is tolerated while continuing immunotherapy.However, the time frame for identifying tumor progression following CAR T-cell therapy in the recurrent setting has not yet been characterized.AIM: Here we report imaging findings from conventional and advanced MRI sequences along with 18-FDG-PET-CT, acquired before, during, and after intracavitary administration of autologous central memory derived IL13Rα2-targeted CAR T-cell therapy for recurrent glioblastoma.METHODS: Imaging findings are reported from an ongoing dose-escalation study (NCT02208362) with maximum doses of 10x10 6 (dose schedule 1), 50x10 6 (dose schedule 2) and 100x10 6 (dose schedule 3) CAR T-cells.All patients underwent MRI scans on a 3T Siemens scanner prior to surgical debulking and CAR T-cell administration as well as at the end of each CAR T-cell treatment cycle, consisting of 3 CAR T-cell infusions into the resection cavity corresponding to time intervals of approximately 1 month.Conventional anatomic MRI included T1-weighted pre-and post-contrast, T2-spin echo, and T2-FLAIR sequences.Quantitative MRI included Dynamic Contrast Enhanced (DCE) Perfusion MRI and Diffusion Weighted Imaging (DWI).Additionally, patients underwent functional metabolic imaging with 18-FDG-PET-CT.Multiparametric imaging characteristics will be compared longitudinally before, during, and following CAR T-cell treatment and correlated to clinical progression.As of May 2018, 14 patients have been treated: dose 1 (n=3), dose 2 (n=3), dose 3 (n=8).Findings and analysis will be updated at the time of late-breaking abstract deadline.
Dextro-Thyroxine as Cholesterol Lowering Agent in Patients with Angina Pectoris
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychologie und Psychotherapie der Herz- und Gefässkranken: Eine klinisch-experimentelle Darstellung für Studierende und praktische Aerzte
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HIBERNATION
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i>-mutant metastatic colorectal cancer (SWOG 1406).
Authors: Scott Kopetz, Shannon L McDonough, Van Karlyle Morris, Heinz-Josef Lenz, Anthony Martin Magliocco, Chloe Evelyn Atreya, Luis A. Diaz, Carmen Joseph Allegra, Stephen E. Wang, Christopher Hanyoung Lieu, S. Gail Eckhardt, Thomas John Semrad, Kimberly Kaberle, Katherine A Guthrie, Howard S. Hochster
Journal: Journal of Clinical Oncology (2017)

520 Background: BRAF V600 mutations are associated with rare objective responses to the mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAF V600 by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. In murine models of BRAF V600 mCRC, the combination of irinotecan, cetuximab, and vemurafenib leads to greater anti-tumor activity, as suggested by a prior Phase 1B study. Methods: Patients (pts) with BRAF V600 mutated and extended RAS wild-type mCRC were randomized to irinotecan (180 mg/m 2 IV every 14 days) and cetuximab (500 mg/m 2 IV every 14 days) with or without vemurafenib (960 mg PO twice daily). Patients had received 1 or 2 prior regimens, with no prior anti-EGFR agents, although prior irinotecan was allowed. Crossover from the control arm to the experimental arm was allowed after documented progression. The primary endpoint was progression-free survival (PFS, investigator assessed), with 90% power to detect a HR of 0.5, with two-sided type 1 error of 5%. Results: 106 patients were enrolled (54 in the experimental arm) from 12/2014 to 4/2016, with ECOG PS ≤ 1. Median age of 62 years, 59% female, and prior irinotecan therapy in 39%. PFS was improved with the addition of vemurafenib (HR = 0.42, 95% confidence interval [CI] of 0.26 to 0.66, P &lt; 0.001) with median PFS of 4.4 (95% CI: 3.6 – 5.7) months vs 2.0 (95% CI: 1.8 – 2.1). Response rate was 16% vs 4% (P = 0.09), with disease control rate of 67% vs 22% (P &lt; 0.001). Grade 3/4 adverse events higher in the experimental arm included neutropenia (28% vs 7%), anemia (13% vs 0%), and nausea (15% vs 0%). There was no increase in skin toxicity or fatigue. No new safety signal was observed. Approximately 50% of patients in the control aim crossed over at the time of progression. Overall survival and efficacy at cross-over data remain immature. Conclusions: The addition of vemurafenib to the combination of cetuximab and irinotecan resulted in a prolongation of progression-free survival and a higher disease control rate, indicating that simultaneous EGFR and BRAF inhibition is effective in BRAF V600 mutated CRC. Clinical trial information: NCT02164916.
New concepts in assessing sickle cell disease severity
Authors: John‐John B. Schnog, Leroy R. Lard, Robert A. Rojer, Fey P.L. Van der Dijs, Frits A.J. Muskiet, Ashley J. Duits
Journal: American Journal of Hematology (1998)

Vasoocclusion leads to pain, chronic organ damage, and a decreased life expectancy in patients with sickle cell disease.Therapeutic options for sickle cell disease have usually been evaluated according to their capacity for reducing the frequency of vasoocclusive crises requiring clinical attention.However, the frequency of vasoocclusive crises is not representative for the rate of accumulating organ damage in most sickle cell patients.This implies that the frequency of vasoocclusive crises needn't correlate with disease severity and, although being of importance, cannot solely serve as a parameter of treatment efficacy.Therefore, additional new objective parameters are needed to effectively study the vasoocclusive process in sickle cell disease.Several studies show that intricate adhesive interactions between (red) blood cells, plasma components, and endothelium play a crucial role in the pathophysiology of sickle cell vasoocclusion, offering new potential parameters to effectively assess disease severity as well as new therapeutical targets in the near future.Whether these adhesive mechanisms involve the causes or the effects of vasoocclusion will be determined if their inhibition, by interventive measures, results in therapeutic benefits.Am.
W. B. ATKINSON, PERMANENT SECRETARY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients.
Authors: Katia Cagossi, Maria Grazia Lazzaretti, Alessia Ferrari, Giorgia Razzini, Meri Leporati, Rosangela Silvestri, Manlio Iadanza, Aldo Iop, Fabrizio Artioli
Journal: Journal of Clinical Oncology (2012)

e11071 Background: Current therapeutic goals for MBC, as an incurable disease, are symptoms and prolonged disease control together with good quality of life. Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. We evaluated the efficacy and tolerability of the combination of anti-angiogenetic activity of metronomic chemotherapy with a tyrosine kinase inhibitor such as lapatinib in heavily pre-treated MBC HER-2 positive patients. Methods: Metastatic breast cancer patients HER-2 positive with CEA or Ca15.3 elevated, measurable disease, prior systemic therapy (chemotherapy and/or hormonal therapy) for advanced disease, ECOG performance status &lt; 1 and life expectancy longer than 3 months. MBC patients were treated with metronomic oral capecitabine (1500 mg daily) and cyclophosphamide (50 mg daily) plus lapatinib (1250 mg daily). The treatment was given until disease progression or unacceptable toxicity. Primary objective was time to progression (TTP) and safety. Results: Tenpatients were included. Median age was 56 years old (range 46-76). Median number of previous chemotherapy lines was 5 (range 2-10). Median time to tumor progression was 4 months (2-7). No complete response was observed. Six out of ten patients (60%) with pre-existing only bone metastases achieved a stable disease and/or partial response and are still on treatment after 6 month of therapy. At the same time 100% of these patients exhibited reduction of serum marker concentrations to normal range. No grade 3-4 toxicity was reported. There was no decline in cardiac function. Hematological and gastro-intestinal toxicity was well tolerated (G1-2). No reduction of dose was needed. Conclusions: The treatment appears to be an effective and less toxic option in heavily pretreated MBC patients. Of note is the observed activity in patients with exclusive bone metastases. Monitoring of CEA and Ca15.3 during the first two months of treatment appears to provide a sensitive and economical means of identifying those patients who are responding to the therapy. Therefore, the combination of lapatinib with metronomic chemotherapy should be explored in advance for osseous MBC.
John Enders Is Scientific Achievement
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Summary of Assessments, 1981
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of intravenous injection of marihuana
Authors: A. B. King
Journal: JAMA (1969)

Two cases of severe illness occurred following the intravenous injection of marihuana. Injection produces immediate severe body tremors with tachycardia, nausea, vomiting, and diarrhea. Diffuse aching pains, hypotension, non-oliguric renal failure, thrombocytopenia, and leukopenia follow. In the cases we saw, all changes have been reversible.